Eurofins Awarded U.S. Government Agreement to Expand National COVID-19 Testing
Regulatory News:
Clinical Enterprise, Inc., a Eurofins Scientific (Paris:ERF) company, today announced it has been awarded a U.S. Government agreement to expand national COVID-19 testing. The agreement with the U.S. Department of Health and Human Services, in coordination with the U.S. Department of Defense (DOD), will expand testing opportunities in K-8 schools, underserved populations and congregate settings such as homeless shelters. Eurofins has been awarded the agreement to test up to 24.6 million people in the Northeast and South regions.
The goals of the government-funded programme are to help identify and minimise asymptomatic transmission, curtail broader community transmission, prevent outbreaks in institutional and community settings, and protect vulnerable individuals and populations.
Vetter gewinnt erneut Axia Best Managed Companies Award
pressnetwork.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pressnetwork.de Daily Mail and Mail on Sunday newspapers.
NORDLB belässt NORDEX AG auf Kaufen
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Keensight Capital to Acquire a Majority Stake in Leading European CRO and CDMO, Symeres, from Gilde Healthcare Private Equity
5/25, 9:00 AM (Source: GlobeNewswire)
PARIS, May 25, 2021 (GLOBE NEWSWIRE)
Keensight Capital, one of the principal private equity managers dedicated to pan-European Growth Buyout investments, has reached an agreement to invest alongside management in Symeres, a leading European drug discovery Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO). According to the terms of the agreement, Keensight Capital will acquire a majority stake in Symeres from the Gilde Healthcare Private Equity fund, a leading European specialist healthcare investor.
Symeres is one of the largest European small molecule CRO & CDMOs, providing R&D services from preclinical drug discovery to Phase I and II clinical stage drug development and manufacturing to major pharmaceutical and bi
Keensight Capital to Acquire a Majority Stake in Leading European CRO and CDMO, Symeres, from Gilde Healthcare Private Equity
May 25, 2021 03:00 ET | Source: Gilde Healthcare Gilde Healthcare
PARIS, May 25, 2021 (GLOBE NEWSWIRE)
Keensight Capital, one of the principal private equity managers dedicated to pan-European Growth Buyout investments, has reached an agreement to invest alongside management in Symeres, a leading European drug discovery Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO). According to the terms of the agreement, Keensight Capital will acquire a majority stake in Symeres from the Gilde Healthcare Private Equity fund, a leading European specialist healthcare investor.